AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 1 mg before each main meal on three separate dosing visits separated by a wash-out period
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: 1 mg before each main meal on three separate dosing visits separated by a wash-out period
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: repaglinide
Description: 1 mg before each main meal on three separate dosing visits separated by a wash-out period
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide
Description: 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
Study NCT02393183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTED
Description: A tablet of ASTED will be taken twice a day
Study NCT02393183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
Study NCT02393183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A tablet of Placebo (same shape and color) will be taken twice a day
Study NCT03218644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobility exercises
Description: Usual treatment and exercises of cervical mobility before a mirror.
Study NCT03218644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception exercises
Description: proprioceptive exercises for craniocervical sensorimotor control.
Study NCT03512132 — intervention group
Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine sample on an empty stomach
Study NCT00092989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Duration of Treatment: 1 dose
Study NCT00092989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Duration of Treatment: 1 dose
Study NCT04377620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered BID approximately 12 hours apart
Study NCT04377620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinb administered BID approximately 12 hours apart
Study NCT00003931 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT03280901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HD, Magnetic Resonance Imaging (MRI) scans
Description: HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
Study NCT05419414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear wave elastography
Description: Both groups were examined with shear wave elastography.
Study NCT01909674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Switch CPAP mask type
Study NCT04030897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-Directed Online Single-Session Program
Description: Online, 15-minute self-administered program for parents
Study NCT04030897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Youth-Directed Online Single-Session Program
Description: Online, 30 minute self-administered program for youths
Study NCT04030897 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information/Psychoeducation/Referral
Description: Usual care at pediatric primary care clinics participating in this study
Study NCT04030897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information/Psychoeducation/Referral
Description: Usual care at pediatric primary care clinics participating in this study
Study NCT03350867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Insole Group
Description: Personalized Insole Group
Study NCT00788567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1
Study NCT01427257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose PB1023
Description: Single Dose PB1023 Formulation A
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glyburide
Description: 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Before each main meal on three separate dosing visits separated by a wash-out period
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Before each main meal on three separate dosing visits separated by a wash-out period
Study NCT01698931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Before each main meal on three separate dosing visits separated by a wash-out period
Study NCT01331681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Study NCT01331681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
Study NCT01331681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser Photocoagulation (Control)
Description: Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Study NCT01427257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose PB1023
Description: Single Dose PB1023 Formulation B
Study NCT01671800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Type B
Study NCT03350867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo Group
Study NCT00818311 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LED GentleWaves®
Description: primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
Study NCT01548417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korlym (mifepristone)
Description: 600 mg/day, oral pill, 7 days
Study NCT01548417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 600 mg/day, oral pill, 7 days
Study NCT03107026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline 4mg
Description: dasotraline 4mg tablet once daily
Study NCT01671800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 30 ml saline 0,375% administered on each side as bilateral TQL blocks
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g orally administered postoperatively
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1 g orally administered postoperatively
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet
Description: orally administered postoperatively
Study NCT03068260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet
Description: orally administered postoperatively
Study NCT03068260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided nerve block
Description: Transmuscular quadratus lumborum block, ultrasound-guided
Study NCT03107026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline 6mg
Description: dasotraline 6mg tablet once daily
Study NCT03107026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study NCT00649051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets 2.5 mg
Description: 4x2.5mg, single dose fasting
Study NCT00649051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaroloxyn® Tablets 2.5 mg
Description: 4x2.5mg, single dose fasting
Study NCT05630560 — intervention group
Intervention type: OTHER
Intervention: Psychotherapy treatment
Description: The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
Study NCT01472991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619-238 5mg
Description: TC-5619-238 5mg capsule taken once daily for 4 weeks
Study NCT01472991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619-238 25mg
Description: TC-5619-238 25mg capsules taken once daily for 4 weeks
Study NCT01472991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be taken once daily for 4 weeks
Study NCT02660866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + background APT + SMT
Description: Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Study NCT02660866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + background APT + SMT
Description: Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Study NCT02660866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vorapaxar 2.08 mg/d + background APT + SMT.
Description: Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Study NCT02660866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorapaxar 2.08 mg/d + background APT + SMT.
Description: Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Study NCT03305406 — intervention group
Intervention type: OTHER
Intervention: Focus groups
Description: Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
Study NCT03399864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical training
Description: The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
Study NCT00435357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile-bearing TKA
Study NCT00435357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed- bearing TKA
Study NCT04249167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04249167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation of the primary tumor
Study NCT03399864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
Study NCT03350451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Multiple doses of lumasiran by SC injection
Study NCT04249167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT01535612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PaQ™ insulin infusion device
Description: Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
Study NCT00996593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
Description: Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
Study NCT02023112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study NCT03435666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELODA
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Study NCT03681054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Study NCT03681054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-protein based diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Study NCT02283242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Oral use for 12 weeks
Study NCT02283242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for galantamine)
Description: Oral use for 12 weeks
Study NCT02023112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule
Study NCT03488238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORi sensor
Description: Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
Study NCT00755872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
Study NCT00755872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
Study NCT00755872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
Study NCT00755872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
Study NCT03154307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repeated TMS (LF-rTMS)
Description: Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
Study NCT03154307 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low frequency repeated TMS (LF-rTMS)
Description: Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
Study NCT01549457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell phone text messages
Description: Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
Study NCT03094819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
Study NCT03094819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retinal Care DR
Description: Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
Study NCT01438307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel-XRP6258 (3-week cycle)
Description: Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
Study NCT01438307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel-XRP6258 (5-week cycle)
Description: Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
Study NCT03657810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108 5 mg
Description: hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
Study NCT03657810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco
Description: hydrocodone 5 mg/APAP 325 mg
Study NCT03657810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching CL-108
Study NCT00669032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: 3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
Study NCT00669032 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
Study NCT01360229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
Study NCT01360229 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture to treat fatigue in Parkinson disease
Description: Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.